These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22488039)

  • 1. The need to compare rilonacept against active treatment for prevention of gout flares: comment on the article by Schumacher et al.
    Abeles AM
    Arthritis Rheum; 2012 Jul; 64(7):2415-6; author reply 2416. PubMed ID: 22488039
    [No Abstract]   [Full Text] [Related]  

  • 2. Allopurinol versus rilonacept for the prevention of gout flares: comment on the article by Schumacher et al.
    Meltzer M
    Arthritis Care Res (Hoboken); 2013 May; 65(5):838. PubMed ID: 23281274
    [No Abstract]   [Full Text] [Related]  

  • 3. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
    Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
    Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.
    Mitha E; Schumacher HR; Fouche L; Luo SF; Weinstein SP; Yancopoulos GD; Wang J; King-Davis S; Evans RR
    Rheumatology (Oxford); 2013 Jul; 52(7):1285-92. PubMed ID: 23485476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in the pharmacotherapy of gout.
    Sundy JS
    Curr Opin Rheumatol; 2010 Mar; 22(2):188-93. PubMed ID: 20110792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lesinurad/allopurinol (Duzallo) for gout-associated hyperuricemia.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):182-183. PubMed ID: 29125593
    [No Abstract]   [Full Text] [Related]  

  • 8. [Febuxostat versus allopurinol for hyperuricemia].
    Ziegler R
    Med Monatsschr Pharm; 2006 Oct; 29(10):384. PubMed ID: 17058902
    [No Abstract]   [Full Text] [Related]  

  • 9. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of hyperuricemia and gout].
    Gröbner W; Walter-Sack I
    Med Monatsschr Pharm; 2005 May; 28(5):159-64; quiz 165-6. PubMed ID: 15912988
    [No Abstract]   [Full Text] [Related]  

  • 11. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
    N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia.
    JAMA; 2018 Jan; 319(2):188-189. PubMed ID: 29318274
    [No Abstract]   [Full Text] [Related]  

  • 13. Febuxostat--treatment for hyperuricemia and gout?
    Moreland LW
    N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of Allopurinol Dose Reduction in Hospitalized Patients With Gout Flares.
    Huang IJ; Bays AM; Liew JW
    J Rheumatol; 2021 Mar; 48(3):467-468. PubMed ID: 33060310
    [No Abstract]   [Full Text] [Related]  

  • 16. Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.
    Sundy JS; Schumacher HR; Kivitz A; Weinstein SP; Wu R; King-Davis S; Evans RR
    J Rheumatol; 2014 Aug; 41(8):1703-11. PubMed ID: 25028379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperuricemia, gout, pseudogout and concomitant diseases].
    Schmidt BM; Wagner AD
    Dtsch Med Wochenschr; 2011 Dec; 136(48):2489-91. PubMed ID: 22109583
    [No Abstract]   [Full Text] [Related]  

  • 18. Recognition and management of gout and hyperuricemia.
    Yennie RH
    JAAPA; 2003 Mar; 16(3):21-4, 27-8, 31. PubMed ID: 14968523
    [No Abstract]   [Full Text] [Related]  

  • 19. Case 9: initiation of urate-lowering therapy for advanced gout complicated by chronic renal insufficiency.
    Edwards NL
    Am J Med; 2006 Nov; 119(11 Suppl 1):S29-31. PubMed ID: 17059911
    [No Abstract]   [Full Text] [Related]  

  • 20. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.